Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
WEBJan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Novartis enters agreement to acquire Mariana Oncology, …
WEBMay 2, 2024 · Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer; Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet need
Chengdu Origen and Vanotech Announce First Patient
WEBNov 21, 2023 · Clinical trial of KH631 evaluates single administration gene-therapy treatment for wet AMD. CHENGDU, China and ROCKAWAY, NJ, USA I November 20, 2023 I Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet ...
Amphista Therapeutics announces new data demonstrating in vivo …
WEBJan 24, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody …
WEBMar 15, 2024 · ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3 + solid tumors. Data will be shared in a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024)
VOYDEYA™ approved in the US as add-on therapy to
WEBApr 2, 2024 · Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial. WILMINGTON, DE, USA I April 01, 2024 I VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). 1 VOYDEYA is a first-in-class, oral, Factor ...
Tetra Therapeutics Announces Positive Topline Results from Phase …
WEBNov 2, 2020 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Alvotech Announces Positive Topline Results from Confirmatory …
WEBJul 3, 2024 · Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpoint
Evive Biotech and Acrotech Biopharma Announce FDA
WEBNov 23, 2023 · – Ryzneuta ® is the first non-pegylated granulocyte colony-stimulating factor approved by both the US Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for treatment for CIN – Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti ...
Skip to content